John Arrotti
Cardiovascular Disease · Palos Park, ILNPI 1790749455
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 532 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,774 and has fallen 93.6% since, to $178 in 2023.
Across 532 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Esperion Therapeutics, Inc.$1K
- AstraZeneca$958
- Novartis$555
- E.r. Squibb & Sons, L.L.C.$530
- Pfizer$491
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,34299%
- Education$421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 108 | $1,415 |
| Esperion Therapeutics, Inc. | 60 | $1,115 |
| AstraZeneca | 38 | $958 |
| Novartis | 39 | $555 |
| E.r. Squibb & Sons, L.L.C. | 53 | $530 |
| Pfizer | 38 | $491 |
| Chiesi USA, Inc. | 32 | $467 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 36 | $455 |
| Amgen | 29 | $450 |
| Boehringer Ingelheim | 15 | $289 |
| Sanofi-aventis U.S. LLC | 19 | $273 |
| Amarin Pharma, Inc. | 16 | $252 |
| Shockwave Medical, Inc | 1 | $176 |
| Medtronic(2 entities) | 3 | $147 |
| Akcea Therapeutics, Inc. | 7 | $142 |
| Kowa Pharmaceuticals America, Inc. | 9 | $139 |
| Novo Nordisk | 4 | $98 |
| Merck | 6 | $82 |
| Regeneron Healthcare Solutions, Inc. | 4 | $72 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Astellas Pharma US Inc | 1 | $24 |
| Abbott | 1 | $23 |
| Lundbeck LLC | 2 | $23 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $17 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Angiodynamics, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,384 in reported general payments places this provider in the 80th percentile of 932 cardiovascular disease providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 30 | $353 |
| Metoprolol Succinate | 27 | $278 |
| ClopidogrelClopidogrel Bisulfate | 13 | $210 |
| Losartan Potassium | 12 | $109 |
| Furosemide | 15 | $108 |
| Levothyroxine Sodium | 12 | $40 |
| Metoprolol Tartrate | 16 | $34 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Palos Park
- Noel CambaPalos Park$130K
- Reema ShethPalos Park$88K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.